ASRS 2020: Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD

Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."

ASRS 2020: Dexamethasone intracameral drug-delivery suspension in vitreoretinal surgery inflammation

Daniel F. Kiernan, MD, FCS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."

ASRS 2020: How one surgeon is integrating recent retina advances in COVID-19

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment

ASRS 2020: Diabetic retinopathy progression in anti-VEGF versus FA implant

August 01, 2020

Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.

Characterizing localized retinal layer changes in AMD

August 01, 2020

Investigators tested the hypothesis that changes in certain areas of the macular are more relevant to AMD. What did their findings reveal?

Vision-related quality of life: Impacts of advanced AMD

August 01, 2020

Why progression to advanced disease may have a more dramatic impact on patients with neovascular AMD compared with those with central geographic atrophy.

Study explores mental health issues in patients with diabetic retinopathy

August 01, 2020

Rates of anxiety and depression increased but were not necessarily tied to disease severity

Considering ethnicity-related differences in macular thickness among diabetics

August 01, 2020

A retrospective study found that in both patients with type 2 diabetes and non-diabetics, average central macular thickness was lower in Asians than Caucasians. Why is this significant for clinicians?

ASRS 2020: AsclepiX lead candidate holds potential for wet AMD, DME, RVO

July 31, 2020

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.

ASRS 2020: What Aviceda’s lead candidate AVD-104 may mean for dry AMD

July 30, 2020

Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.

ASRS 2020: Evaluating 3-year-recurrence rate in non-infectious posterior segment veitis post-FAi

July 29, 2020

Dilraj Grewal, MD, associate professor of ophthalmology at Duke Eye Center/ director of grading at the Duke Reading Center, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during the virtual 2020 ASRS meeting.

ASRS 2020: Alcon showcases latest retina innovations, data

July 28, 2020

ASRS 2020: Josh Anderson speaks on the highlights from Alcon, including new data on the performance benefits of the Hypervit dual blade 20,000 cpm probe and the launch of the NGENUITY 1.4 upgrade.

ASRS 2020: PDS with ranibizumab signals paradigm shift in treatment of neovascular AMD

July 27, 2020

PDS with ranibizumab is proving to be an innovation solution for nAMD patients. Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 ASRS annual meeting.